Table 4.
Comparison of the pharmacokinetics of ODF formulations from IBSA with film‐coated tablet formulation and ODT formulation, both from Pfizer (De Toni et al., 2018)
| Film‐coated tablet formulation from Pfizer | ODT formulation from Pfizer | ODF formulation from IBSA | |
|---|---|---|---|
| Cmax (ng/mL) | 49 | 46 | 38 |
| AUC (ng h/mL) | 6180 | 4623 | 5898 |
| Tmax (ng/mL), meana | 95 | 90 | 70 |
| Tonset (10 ng/mL)b | 13.5 | 25.5 | 40 |
| Tonset (20 ng/mL)b | 21.5 | 39 | 57 |
| Adverse effects | |||
| Nasal congestion | 40% | 25% | 30% |
| Flushing | 50% | 20% | 20% |
| Headache | 35% | 30% | 5% |
a
Non‐fasting patients.
b
Derived from a figure of De Toni et al. study.